NEUROPATHIC PAIN: FROM PATHOGENESIS AND CLINICS TO DIFFERENTIATED THERAPY


Cite item

Full Text

Abstract

Chronic neuropathic syndromes are relevant medical problem because they are widespread in clinical practice and lead to significant maladjustment of patients. Pathophysiological processes in the formation and development of neuropathic syndrome are clearly correlated with the clinical picture of neuropathic pain, therefore, detailed analysis of the clinical presentation is extremely important for the selection of pathogenetically justified treatment. The article is concerned with analysis of clinical manifestations and mechanisms of development of symptom in neuropathic pain, which is the basis for optimization of treatment with the use of pathogenetic therapy.

References

  1. Алексеев В.В. Невропатическая боль: симптомы, механизмы, терапия // Consilium-medicum. 2010. № 2. С. 52-9.
  2. Баринов А.Н. Лечение невропатических болевых синдромов // РМЖ. 2003. № 25. С. 1419-22.
  3. Баринов А.Н. Роль гомосинаптической стимулзависимой нейрональной пластичности (феномена "взвинчивания") в хронификации болевых синдромов // Consilium Medicum. 2010. № 2.
  4. Баринов А.Н. Современные достижения в понимании механизмов формирования и лечения хронической боли // Неврологический журнал. 2003. № 5б. С. 57-61.
  5. Боль. Руководство для врачей и студентов / Под редакцией Яхно Н.Н. М., 2009. C. 304.
  6. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М., 2007. C. 192.
  7. Кукушкин М.Л. Тактика ведения пациента с невропатической болью // Справочник поликлинического врача. 2009. № 10. С. 39-47.
  8. Невропатическая боль: клинические наблюдения / Под редакцией Яхно Н.Н. и др. М., 2009.C. 264.
  9. Романенко С.В., Костюк П.Г., Костюк Е.П. Перспективы применения препарата габагамма для лечения диабетических полинейропатий // Наука та інновації. 2009. № 6. С. 64-9.
  10. Строков И.А., Ахмеджанова Л.Т. Лечение невропатической боли при диабетической полиневропатии // РМЖ 2008.Т. 16. № 28.
  11. Чурюканов М.В. Основные положения рекомендаций Европейской федерации неврологических обществ (EFNS) по диагностике и медикаментозному лечению невропатической боли // Боль 2007. № 3. С. 38-45.
  12. Яхно Н.Н., Баринов А.Н., Подчуфарова Е.В. Невропатическая и скелетно-мышечная боль. Современные подходы к диагностике и лечению // Клиническая медицина 2008. № 11. С. 9-15.
  13. Яхно Н.Н., Кукушкин М.Л., Давыдов О.С. и др. Результаты Российского эпидемиологического исследования распространенности невропатической боли, ее причин и характеристик в популяции амбулаторных больных, обратившихся к врачу-неврологу // Боль 2008. № 3. С. 24-32.
  14. Яхно Н.Н., Кукушкин М.Л., Давыдов О.С. и др. Результаты Российского эпидемиологического исследования распространенности невропатической боли (EPIC Study). Лечение невропатической боли // Consilium-medicum. 2008. № 2.
  15. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. Eur J Neurol 2010.
  16. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006;13:1153-69.
  17. Baron R, et al. Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to the generation of pain? Muscle Nerve 1999;22:678-95.
  18. Baron R. Mechanisms of disease: neuropathic pain - a clinical perspective. Nature Clinical Practice Neurology 2006;2:95-106.
  19. Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the α2δ protein J Med Chem 2005;48:2294-07.
  20. Bonhaus DW, Loo C, Secchi R, et al. Effects of the GABAB receptor antagonist CGP 55845 on the anticonvulsant and anxiolytic actions of gabapentin. (XIVth World Congress of Pharmacology, San Francisco: ASPET) Pharmacologist 2002;44:100.
  21. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333.
  22. Catarina MJ, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000;288:306-13.
  23. Cheng JK, Ciou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci 2006;100:471-86.
  24. Chizh BA, Scheede M, Schlutz H. Antinociception and (R,S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid antagonism by gabapentin in the rat spinal cord in vivo. Naunyn Schmiedebergs Arch Pharmacol 2000;362:197-200.
  25. Chou R, Norris SL, Carson S, et al. Drug Class Review on Drugs for Neuropathic Pain: Final Report. Portland (OR): Oregon Health & Science University. 2007.
  26. Cruccua G, Sommera C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010.
  27. Dissanayake VU, Gee NS, Brown JP, et al. Spermine modulation of specific [3H]-gabapentin binding to the detergentsolubilized porcine cerebral cortex α2δ calcium channel subunit. Br J Pharmacol 1997;120:833-40.
  28. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-06.
  29. Gu Y, Huang LY. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neurosci Lett 2002;324:177-80.
  30. Hong S, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J Biol Chem 2005;280:618-27.
  31. Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995;692:273-77.
  32. Lai J, et al. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 2003;13:291-97.
  33. Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and noninflammatory neuropathies. Acta Neuropathol 2003;105:593-602.
  34. Marchand F, et al. Role of the immune system in chronic pain. Nat Rev Neurosci 2005;6:521-53.
  35. Moore KA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002;22:6724-31.
  36. Patapoutian A, et al. ThermoTRP channels and beyond: mechanisms of temperature sensation. Nat Rev Neurosci 2003;4:529-39.
  37. Price MP, et al. The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron 2001;32:1071-83.
  38. Sarantopoulos C, McCallum B, Sapunar D, et al. ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin. Neurosci Lett 2003;343:185-89.
  39. Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia 2003;44:150-56.
  40. Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-89.
  41. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-35.
  42. Wamil AW, McLean MJ. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 1994;17:1-11.
  43. Wieseler-Frank J, et al. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005;14:166-74.
  44. Wood JN. Voltage-gated sodium channels and pain pathways. J Neurobiol 2004;61:55-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies